At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
Belataceptdrug
Likely dose
Belatacept 7.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant
In Brief
A Phase 2 clinical trial evaluating Belatacept for Kidney Transplant. Completed, enrolled 16 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate how well adolescent kidney transplant patients tolerate a single dose of belatacept they receive at least 6 months after transplant surgery, and how their body handles the drug.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplant
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartMay 2013
Primary CompletionDec 2016
TodayJul 2026
First PostedFeb 15, 2013
Enrollment StartMay 9, 2013
Primary CompletionDec 6, 2016
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 13.4 years ago
Interventions
Belataceptdrug
Single intravenous infusion of belatacept, 7.5 mg/kg